Company news
Xenetic Biosciences, Inc. news in 2024
Xenetic Biosciences, Inc.'s news releases, calls and decks from 2024, newest first.
Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
December 15, 2024
Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program
December 4, 2024
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
November 20, 2024
Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results
November 12, 2024
Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models
November 11, 2024
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
November 6, 2024
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
October 21, 2024
Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform
October 16, 2024
Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference
September 10, 2024
Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
August 13, 2024
Xenetic Biosciences, Inc. Announces Executive Leadership Transition
May 21, 2024
Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
May 9, 2024
Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results
March 21, 2024
Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
January 16, 2024